regn4018
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 21, 2018 (NCT03564340)
Timeline
Indications
Mechanism of action
- Mucin-16INHIBITOR
MUC16 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594595 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07154290 | Phase 2 | Jan 26, 2026 | Regeneron |
| NCT06787612 | Phase 2 | May 1, 2025 | Regeneron |
| NCT06444880 | Phase 2 | Oct 9, 2024 | Regeneron, University of Texas at Houston |
| NCT04590326 | Phase 1/Phase 2 (Phase 2) | Nov 20, 2020 | Regeneron |
| NCT03564340 | Phase 1/Phase 2 (Phase 2) | May 21, 2018 | Regeneron |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 5 | 4 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1